Safety and Immunogenicity of Heterologous Boosting With Orally Aerosolised or Intramuscular Ad5-nCoV Vaccine and Homologous Boosting With Inactivated Vaccines
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Respiratory Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Safety and immunogenicity of heterologous boosting with orally aerosolised or intramuscular Ad5-nCoV vaccine and homologous boosting with inactivated vaccines (BBIBP-CorV or CoronaVac) in children and adolescents: a randomised, open-label, parallel-controlled, non-inferiority, single-centre study
Lancet Respir Med 2023 May 17;[EPub Ahead of Print], T Huang, S Zhang, DF Dai, BS Wang, L Zhuang, HT Huang, ZF Wang, JS Zhao, QP Li, SP Wu, X Wang, WD Zhang, ZH Zhao, H Li, YP Zhang, XL Yang, XY Jiang, JB Gou, LH Hou, LD Gao, ZC FengFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.